Experimental drug combo offers hope for Tough-to-Treat blood cancers
NCT ID NCT03896269
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a chemotherapy drug called CPX-351 in people with high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) that came back or didn't respond to standard treatment. The goal is to find the best dose that is safe and to see if it can shrink or control the cancer. About 38 adults will take part in this study at MD Anderson Cancer Center.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTS 10-19 PERCENT OF BONE MARROW NUCLEATED CELLS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could early comfort care change End-of-Life for blood cancer patients?
- Second chance: vyxeos targets tough leukemia after standard chemo fails
- New combo attack on stubborn leukemia: chemo then transplant
- New drug combo shows promise for Hard-to-Treat bone marrow disease
- New drug combo aims to shrink Hard-to-Treat blood cancers
- New pill targets hard-to-treat blood cancers in early trial